Common Proprotein convertase subtilisin/kexin type 9 (PCSK9) epitopes mediate multiple routes for internalization and function

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  De Vay, Rachel M ^a   Yamamoto, Lynn ^a   Shelton, David L ^a   Liang, Hong ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR LIKE PROTEIN 2; APOLIPOPROTEIN E RECEPTOR 2; EPITOPE; LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR; PROTEIN PRECURSOR; SUBTILISIN; UNCLASSIFIED DRUG; AMYLOID PRECURSOR PROTEIN; APLP2 PROTEIN, HUMAN; LDLR PROTEIN, HUMAN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 8; NERVE PROTEIN; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9; PROTEIN BINDING; SERINE PROTEINASE;

ANIMAL CELL; ARTICLE; BINDING COMPETITION; CONTROLLED STUDY; ENDOCYTOSIS; HUMAN; HUMAN CELL; INTERNALIZATION; LIVER CELL; LYSOSOME; MOUSE; NONHUMAN; PH; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN TRANSPORT; RECEPTOR BINDING; ANIMAL; CHEMISTRY; HEP-G2 CELL LINE; MALE; METABOLISM;

AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ENDOCYTOSIS; EPITOPES; HEP G2 CELLS; HEPATOCYTES; HUMANS; HYDROGEN-ION CONCENTRATION; LDL-RECEPTOR RELATED PROTEINS; LYSOSOMES; MALE; MICE; NERVE TISSUE PROTEINS; PROPROTEIN CONVERTASE 9; PROPROTEIN CONVERTASES; PROTEIN BINDING; RECEPTORS, LDL; SERINE ENDOPEPTIDASES;

EID: 84930685891     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0125127     Document Type: Article

References (33)

1. Jeon H, BlacklowSC. Structure and physiologic function of the low-density lipoprotein receptor. Annual review of biochemistry. 2005;74:535-62. PMID: 15952897.
2. Nassoury N, Blasiole DA, Tebon OlerA, BenjannetS, Hamelin J, Poupon V, et al. The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR. Traffic (Copenhagen, Denmark). 2007;8(6):718-32. PMID: 17461796.
3. Kwon HJ, LagaceTA, McNutt MC, Horton JD, Deisenhofer J. Molecular basis for LDL receptor recognition by PCSK9. Proceedings of the National Academy of Sciences of the United States of America. 2008;105(6):1820-5. PMID: 18250299. doi: 10.1073/pnas.0712064105
4. Lagace TA, Curtis DE, Garuti R, McNutt MC, Park SW, Prather HB, et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. The Journal of clinical investigation. 2006;116(11):2995-3005. PMID: 17080197.
5. McNutt MC, Lagace TA, Horton JD. Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells. The Journal of biological chemistry. 2007;282(29):20799-803. PMID: 17537735.
6. Jonas MC, Costantini C, Puglielli L. PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1. EMBO reports. 2008;9(9):916-22. PMID: 18660751. doi: 10.1038/embor.2008.132
7. Shan L, Pang L, Zhang R, Murgolo NJ, Lan H, Hedrick JA. PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide. Biochemical and biophysical research communications. 2008;375(1):69-73. PMID: 18675252. doi: 10.1016/j.bbrc.2008.07.106
8. PoirierS, Mayer G, BenjannetS, Bergeron E, Marcinkiewicz J, Nassoury N, et al. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. The Journal of biological chemistry. 2008;283(4):2363-72. PMID: 18039658.
9. Canuel M, Sun X, Asselin MC, Paramithiotis E, Prat A, Seidah NG. Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1). PloSone. 2013;8(5):e64145. doi: 10.1371/journal.pone.0064145 PMID: 23675525; PubMed Central PMCID: PMC3652815.
10. Luna SaavedraYG, Day R, Seidah NG. The M2 module of the Cys-His-rich domain (CHRD) of PCSK9 is needed for the extracellular low density lipoprotein receptor (LDLR) degradation pathway. The Journal of biological chemistry. 2012. PMID: 23105118.
11. Ni YG, Condra JH, Orsatti L, Shen X, Di Marco S, Pandit S, et al. A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake. The Journal of biological chemistry. 2010;285(17):12882-91. PMID: 20172854. doi: 10.1074/jbc. M110.113035
12. Surdo PL, Bottomley MJ, CalzettaA, Settembre EC, CirilloA, Pandit S, et al. Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH. EMBO reports. 2011. PMID: 22081141.
13. Holla OL, Cameron J, Tveten K, Strom TB, Berge KE, Laerdahl JK, et al. Role of the C-terminal domain of PCSK9in degradation of the LDL receptors. Journal of lipid research. 2011;52(10):1787-94. PMID: 21771976. doi: 10.1194/jlr. M018093
14. DeVay RM, Shelton DL, Liang H. Characterization of proprotein convertase subtilisin/kexin type 9 (PCSK9) trafficking reveals a novel lysosomal targeting mechanism via amyloid precursor-like protein 2 (APLP2). The Journal of biological chemistry. 2013;288(15):10805-18. doi: 10.1074/jbc. M113.453373 PMID: 23430252; PubMed Central PMCID: PMC3624461.
15. Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nature genetics. 2005;37(2):161-5. PMID: 15654334.
16. Cohen JC, Boerwinkle E, Mosley TH Jr., Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. The New England journal of medicine. 2006;354(12):1264-72. PMID: 16554528.
17. Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nature genetics. 2003;34(2):154-6. PMID: 12730697.
18. Maxwell KN, Breslow JL. Proprotein convertase subtilisin kexin 9: the third locus implicated in autosomal dominant hypercholesterolemia. Current opinion in lipidology. 2005;16(2):167-72. PMID: 15767856.
19. Chaparro-Riggers J, Liang H, DeVay RM, Bai L, Sutton JE, Chen W, et al. Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9. The Journal of biological chemistry. 2012;287(14):11090-7. doi: 10.1074/jbc. M111.319764 PMID: 22294692; PubMed Central PMCID: PMC3322827.
20. Chan JC, Piper DE, CaoQ, Liu D, KingC, WangW, et al. Aproprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proceedings of the National Academy of Sciences of the United States of America. 2009;106(24):9820-5. PMID: 19443683. doi: 10.1073/pnas.0903849106
21. Ni YG, Di Marco S, Condra JH, Peterson LB, WangW, Wang F, et al. A PCSK9-binding antibody that structurally mimics the EGF (A) domain of LDL-receptor reduces LDL cholesterol in vivo. Journal of lipid research. 2011;52(1):78-86. PMID: 20959675. doi: 10.1194/jlr. M011445
22. Liang H, Chaparro-Riggers J, Strop P, Geng T, Sutton JE, Tsai D, et al. PCSK9 Antagonism Reduces LDL-cholesterol in Statin-treated Hypercholesterolemic Non-human Primates. The Journal of pharmacology and experimental therapeutics. 2012. PMID: 22019884.
23. Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. The New England journal of medicine. 2012;367(20):1891-900. doi: 10.1056/NEJMoa1201832 PMID: 23113833.
24. Stein EA, Gipe D, Bergeron J, Gaudet D, Weiss R, Dufour R, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012;380(9836):29-36. doi: 10.1016/S0140-6736 (12) 60771-5 PMID: 22633824.
25. McNutt MC, Kwon HJ, Chen C, Chen JR, Horton JD, Lagace TA. Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells. The Journal of biological chemistry. 2009;284(16):10561-70. PMID: 19224862. doi: 10.1074/jbc. M808802200
26. Fisher TS, LoSurdo P, Pandit S, Mattu M, Santoro JC, Wisniewski D, et al. Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation. The Journal of biological chemistry. 2007;282(28):20502-12. PMID: 17493938.
27. Fan D, Yancey PG, Qiu S, Ding L, WeeberEJ, Linton MF, et al. Self-association of human PCSK9 correlates with its LDLR-degrading activity. Biochemistry. 2008;47(6):1631-9. PMID: 18197702. doi: 10. 1021/bi7016359
28. Tavori H, Fan D, Blakemore JL, Yancey PG, Ding L, Linton MF, et al. Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation. Circulation. 2013;127(24):2403-13. doi: 10.1161/CIRCULATIONAHA.113.001592 PMID: 23690465; PubMed Central PMCID: PMC3806304.
29. Kosenko T, Golder M, Leblond G, Weng W, Lagace TA. Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation. The Journal of biological chemistry. 2013;288(12):8279-88. doi: 10. 1074/jbc. M112.421370 PMID: 23400816; PubMed Central PMCID: PMC3605646.
30. Schmidt RJ, BeyerTP, Bensch WR, Qian YW, Lin A, Kowala M, et al. Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo. Biochemical and biophysical research communications. 2008;370(4):634-40. PMID: 18406350. doi: 10.1016/j.bbrc.2008.04.004
31. Grefhorst A, McNutt MC, Lagace TA, Horton JD. Plasma PCSK9 preferentially reduces liver LDL receptors in mice. Journal of lipid research. 2008;49(6):1303-11. PMID: 18354138. doi: 10.1194/jlr. M800027-JLR200
32. PoirierS, Mayer G, Poupon V, McPherson PS, Desjardins R, Ly K, et al. Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route. The Journal of biological chemistry. 2009;284(42):28856-64. PMID: 19635789. doi: 10.1074/jbc. M109.037085
33. Strom TB, Tveten K, Holla OL, Cameron J, Berge KE, Leren TP. The cytoplasmic domain is not involved in directing Class 5 mutant LDL receptors to lysosomal degradation. Biochemical and biophysical research communications. 2011;408(4):642-6. doi: 10.1016/j.bbrc.2011.04.077 PMID: 21531209.